Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Joseph Robinson

Cardiovascular Disease Washington, DC Medical Doctor

NPI 1497717458 CMS profile 158045

106 Irving St Nw Ste 3000N, Washington, DC 20010

Open in the dashboard

General payments

$2,407

105 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Joseph Robinson of Washington, DC is reported in the CMS Open Payments database as having received $2,407 across 105 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 54th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $638 33
2021 General $422 21
2020 General $282 15
2019 General $1,066 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Robinson
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Joseph Robinson were reported at $0. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Joseph Robinson Cardiovascular Disease median Middle half National median
2019 $1,066 $450 $127–$1,392 $163
2020 $282 $242 $77–$751 $114
2021 $422 $335 $101–$1,037 $132
2022 $638 $395 $121–$1,211 $149
2023 $0 $443 $136–$1,283 $160
2024 $0 $450 $136–$1,323 $164
2025 $0 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Novartis Pharmaceuticals Corporation $424 18 payments
  2. Abbott Laboratories $334 3 payments
  3. Merck Sharp & Dohme Corporation $259 14 payments
  4. Novo Nordisk Inc $214 12 payments
  5. Pfizer Inc. $188 8 payments
  6. Lilly USA, LLC $180 10 payments
  7. AstraZeneca Pharmaceuticals LP $175 9 payments
  8. Amgen Inc. $157 8 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $135 6 payments
  10. Sanofi-Aventis U.S. LLC $68 3 payments
  11. Other $275 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $2,361 102 payments
  2. Education $46 3 payments
Products named General payments · program years 2019–2022
  1. ENTRESTO $424 18 payments
  2. VERQUVO $259 14 payments
  3. Assurity Pacemaker $174 1 payment
  4. TRULICITY $163 9 payments
  5. ELIQUIS $160 7 payments
  6. Ozempic $158 9 payments
  7. RYBELSUS $158 9 payments
  8. Repatha $157 8 payments
  9. Confirm Rx $137 1 payment
  10. JARDIANCE $130 7 payments
  11. Other $1,397 70 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

105 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in District of Columbia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record